REVIEW Azelnidipine is a dihydropyridine calcium channel blocker with selectivity for L-type calcium channels that is approved in Japan for the treatment of patients with hypertension. It has a gradual onset and has a long-lasting hypotensive effect, with little increase in heart rate. Azelnidipine is approved for use in treating ischemic heart disease and cardiac remodeling after myocardial infarction. Azelnidipine has also been shown to have antioxidant effects in endothelial cells and cardiomyocytes.
Oizumi K, Nishino H, Koike H, Sada T, Miyamoto M, Kimura, Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker, Jpn. J. Pharmacol. 1989, 51 (1): 57-64.
Arita M, Hashizume T, Tanigawa K, Yamamoto H, Nishio I. A new Ca-antagonist, azelnidipine, reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension: a randomized, double-blind, placebo-controlled trial. J Cardiovasc Pharmacol. 1999 Feb;33(2):186-92.
For research use only. Not for diagnostic or therapeutic use. Not for human use. AK Scientific, Inc. does not sell to individuals. If you are a first-time customer, please email for review at least two official business documents issued by your local jurisdiction, state/province, or country.